Abstract
The mechanisms involved in the tumor-stroma interaction during carcinoma progression are an area of intensive investigation. Cancer cells produce a range of growth factors and proteolytic enzymes that modify their stromal environment. These factors disrupt normal tissue homeostasis and act in a paracrine manner to induce angiogenesis and inflammation, as well as activation of surrounding stromal cell types such as fibroblasts, smooth-muscle cells and adipocytes, leading to the secretion of additional growth factors and proteases. Recent studies reveal that fibroblasts have more profound influence on the development and progression of carcinoma than was previously appreciated. These cancer-associated fibroblasts (CAFs) are a heterogeneous fibroblast population with different life-span which are activated and recruited during carcinoma progression. One of the more provocative implications is that genetically altered or/and senescence fibroblasts can induce epithelial cells to form carcinomas. In this article, we will review some evidences that CAFs produce a number of paracrine factors that affect several aspects of pleural and urothelial cancer progression. Moreover, we discuss how this new perspectives on the role of CAFs during cancer initiation and progression can have important implications to cancer therapy.
Keywords: CAFs, tumor stroma, myofibroblasts, pleural cancer, urothelial cancer
Current Signal Transduction Therapy
Title: Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Volume: 1 Issue: 3
Author(s): Maria Rita Rippo, Antonio Procopio and Alfonso Catalano
Affiliation:
Keywords: CAFs, tumor stroma, myofibroblasts, pleural cancer, urothelial cancer
Abstract: The mechanisms involved in the tumor-stroma interaction during carcinoma progression are an area of intensive investigation. Cancer cells produce a range of growth factors and proteolytic enzymes that modify their stromal environment. These factors disrupt normal tissue homeostasis and act in a paracrine manner to induce angiogenesis and inflammation, as well as activation of surrounding stromal cell types such as fibroblasts, smooth-muscle cells and adipocytes, leading to the secretion of additional growth factors and proteases. Recent studies reveal that fibroblasts have more profound influence on the development and progression of carcinoma than was previously appreciated. These cancer-associated fibroblasts (CAFs) are a heterogeneous fibroblast population with different life-span which are activated and recruited during carcinoma progression. One of the more provocative implications is that genetically altered or/and senescence fibroblasts can induce epithelial cells to form carcinomas. In this article, we will review some evidences that CAFs produce a number of paracrine factors that affect several aspects of pleural and urothelial cancer progression. Moreover, we discuss how this new perspectives on the role of CAFs during cancer initiation and progression can have important implications to cancer therapy.
Export Options
About this article
Cite this article as:
Rita Rippo Maria, Procopio Antonio and Catalano Alfonso, Emerging Role of Stromal Fibroblasts in Epithelial Cancer, Current Signal Transduction Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157436206778226969
DOI https://dx.doi.org/10.2174/157436206778226969 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prognostic and Predictive Value of Epithelial to Mesenchymal Transitionassociated Markers in Oral Squamous Cell Carcinoma
Current Proteomics Novel Non-Steroidal Anti-Inflammatory Drugs: What we have Learned from Animal Studies
Current Drug Targets - Inflammation & Allergy Structure and Function of the Epstein-Barr Virus Transcription Factor, EBNA 3C
Current Protein & Peptide Science Dual Role of S100A8 and S100A9 in Inflammation-Associated Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics Expression of Cytochrome P450 in Lung Tumor
Current Drug Metabolism Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Blockade of Jagged/Notch Pathway Abrogates Transforming Growth Factor β2-Induced Epithelial-Mesenchymal Transition in Human Retinal Pigment Epithelium Cells
Current Molecular Medicine Autophagy: Molecular Mechanisms and their Implications for Anticancer Therapies
Current Cancer Drug Targets Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Organic Cation Transporters: Physiology, Toxicology and Special Focus on Ethidium as a Novel Substrate
Current Drug Metabolism Therapeutic Targeting of CPT-11 Induced Diarrhea: A Case for Prophylaxis
Current Drug Targets Ovulation Inducing Agents and Cancer Risk: Review of Literature
Current Drug Safety Protein Tyrosine Phosphatases, New Targets for Cancer Therapy
Current Cancer Drug Targets Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy
Current Pharmaceutical Design The Role of Transforming Growth Factor β1 in the Regulation of Blood Pressure
Current Hypertension Reviews Adrenergic Receptors as Targets for Cancer Treatment - A Perspective for Future Studies
Current Cancer Therapy Reviews Regulation of Autophagy by Sphingolipids
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in the Diagnosis and Therapy of Primary Adrenal Insufficiency
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents